Close
KTAR.com
News
Shows
Blogs
KTAR News on 92.3FM

Most vulnerable still in jeopardy as COVID precautions ease

Bottles and syringes holding a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, rest on a table, Thursday, Jan. 20, 2022 at a University of Washington Medicine clinic in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, is reflected in a mirror, Thursday, Jan. 20, 2022, as he talks with a reporter after being given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Jose Lazaro, a medical assistant at a University of Washington Medicine clinic, prepares a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, right, who is immune-compromised, is given a shot of the two-shot dose of AstraZeneca's Evusheld — the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, by Jose Lazaro, center, a medical assistant at a University of Washington Medicine clinic in Seattle as Cynde Wiederhold, left, a nurse, looks on. The two-shot dose is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, holds a photo of himself taken in 2020 when he received a liver transplant, Thursday, Jan. 20, 2022, after he was given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Bottles and syringes holding a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, rest on a table, Thursday, Jan. 20, 2022 at a University of Washington Medicine clinic in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, is reflected in a mirror, Thursday, Jan. 20, 2022, as he talks with a reporter after being given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Jose Lazaro, a medical assistant at a University of Washington Medicine clinic, prepares a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, right, who is immune-compromised, is given a shot of the two-shot dose of AstraZeneca's Evusheld — the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, by Jose Lazaro, center, a medical assistant at a University of Washington Medicine clinic in Seattle as Cynde Wiederhold, left, a nurse, looks on. The two-shot dose is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, holds a photo of himself taken in 2020 when he received a liver transplant, Thursday, Jan. 20, 2022, after he was given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Bottles and syringes holding a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, rest on a table, Thursday, Jan. 20, 2022 at a University of Washington Medicine clinic in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, is reflected in a mirror, Thursday, Jan. 20, 2022, as he talks with a reporter after being given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Jose Lazaro, a medical assistant at a University of Washington Medicine clinic, prepares a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, right, who is immune-compromised, is given a shot of the two-shot dose of AstraZeneca's Evusheld — the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, by Jose Lazaro, center, a medical assistant at a University of Washington Medicine clinic in Seattle as Cynde Wiederhold, left, a nurse, looks on. The two-shot dose is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, holds a photo of himself taken in 2020 when he received a liver transplant, Thursday, Jan. 20, 2022, after he was given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Bottles and syringes holding a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, rest on a table, Thursday, Jan. 20, 2022 at a University of Washington Medicine clinic in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, is reflected in a mirror, Thursday, Jan. 20, 2022, as he talks with a reporter after being given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Jose Lazaro, a medical assistant at a University of Washington Medicine clinic, prepares a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, right, who is immune-compromised, is given a shot of the two-shot dose of AstraZeneca's Evusheld — the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, by Jose Lazaro, center, a medical assistant at a University of Washington Medicine clinic in Seattle as Cynde Wiederhold, left, a nurse, looks on. The two-shot dose is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, holds a photo of himself taken in 2020 when he received a liver transplant, Thursday, Jan. 20, 2022, after he was given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Bottles and syringes holding a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, rest on a table, Thursday, Jan. 20, 2022 at a University of Washington Medicine clinic in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, is reflected in a mirror, Thursday, Jan. 20, 2022, as he talks with a reporter after being given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Jose Lazaro, a medical assistant at a University of Washington Medicine clinic, prepares a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, right, who is immune-compromised, is given a shot of the two-shot dose of AstraZeneca's Evusheld — the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, by Jose Lazaro, center, a medical assistant at a University of Washington Medicine clinic in Seattle as Cynde Wiederhold, left, a nurse, looks on. The two-shot dose is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, holds a photo of himself taken in 2020 when he received a liver transplant, Thursday, Jan. 20, 2022, after he was given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Bottles and syringes holding a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, rest on a table, Thursday, Jan. 20, 2022 at a University of Washington Medicine clinic in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, is reflected in a mirror, Thursday, Jan. 20, 2022, as he talks with a reporter after being given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Jose Lazaro, a medical assistant at a University of Washington Medicine clinic, prepares a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, right, who is immune-compromised, is given a shot of the two-shot dose of AstraZeneca's Evusheld — the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, by Jose Lazaro, center, a medical assistant at a University of Washington Medicine clinic in Seattle as Cynde Wiederhold, left, a nurse, looks on. The two-shot dose is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, holds a photo of himself taken in 2020 when he received a liver transplant, Thursday, Jan. 20, 2022, after he was given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Bottles and syringes holding a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, rest on a table, Thursday, Jan. 20, 2022 at a University of Washington Medicine clinic in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, is reflected in a mirror, Thursday, Jan. 20, 2022, as he talks with a reporter after being given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Jose Lazaro, a medical assistant at a University of Washington Medicine clinic, prepares a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, right, who is immune-compromised, is given a shot of the two-shot dose of AstraZeneca's Evusheld — the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, by Jose Lazaro, center, a medical assistant at a University of Washington Medicine clinic in Seattle as Cynde Wiederhold, left, a nurse, looks on. The two-shot dose is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, holds a photo of himself taken in 2020 when he received a liver transplant, Thursday, Jan. 20, 2022, after he was given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Bottles and syringes holding a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, rest on a table, Thursday, Jan. 20, 2022 at a University of Washington Medicine clinic in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, is reflected in a mirror, Thursday, Jan. 20, 2022, as he talks with a reporter after being given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Jose Lazaro, a medical assistant at a University of Washington Medicine clinic, prepares a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, right, who is immune-compromised, is given a shot of the two-shot dose of AstraZeneca's Evusheld — the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, by Jose Lazaro, center, a medical assistant at a University of Washington Medicine clinic in Seattle as Cynde Wiederhold, left, a nurse, looks on. The two-shot dose is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, holds a photo of himself taken in 2020 when he received a liver transplant, Thursday, Jan. 20, 2022, after he was given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Bottles and syringes holding a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, rest on a table, Thursday, Jan. 20, 2022 at a University of Washington Medicine clinic in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, is reflected in a mirror, Thursday, Jan. 20, 2022, as he talks with a reporter after being given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Jose Lazaro, a medical assistant at a University of Washington Medicine clinic, prepares a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, right, who is immune-compromised, is given a shot of the two-shot dose of AstraZeneca's Evusheld — the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, by Jose Lazaro, center, a medical assistant at a University of Washington Medicine clinic in Seattle as Cynde Wiederhold, left, a nurse, looks on. The two-shot dose is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, holds a photo of himself taken in 2020 when he received a liver transplant, Thursday, Jan. 20, 2022, after he was given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Bottles and syringes holding a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, rest on a table, Thursday, Jan. 20, 2022 at a University of Washington Medicine clinic in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, is reflected in a mirror, Thursday, Jan. 20, 2022, as he talks with a reporter after being given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Jose Lazaro, a medical assistant at a University of Washington Medicine clinic, prepares a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, right, who is immune-compromised, is given a shot of the two-shot dose of AstraZeneca's Evusheld — the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, by Jose Lazaro, center, a medical assistant at a University of Washington Medicine clinic in Seattle as Cynde Wiederhold, left, a nurse, looks on. The two-shot dose is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, holds a photo of himself taken in 2020 when he received a liver transplant, Thursday, Jan. 20, 2022, after he was given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Bottles and syringes holding a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, rest on a table, Thursday, Jan. 20, 2022 at a University of Washington Medicine clinic in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, is reflected in a mirror, Thursday, Jan. 20, 2022, as he talks with a reporter after being given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Jose Lazaro, a medical assistant at a University of Washington Medicine clinic, prepares a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, right, who is immune-compromised, is given a shot of the two-shot dose of AstraZeneca's Evusheld — the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, by Jose Lazaro, center, a medical assistant at a University of Washington Medicine clinic in Seattle as Cynde Wiederhold, left, a nurse, looks on. The two-shot dose is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, holds a photo of himself taken in 2020 when he received a liver transplant, Thursday, Jan. 20, 2022, after he was given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Bottles and syringes holding a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, rest on a table, Thursday, Jan. 20, 2022 at a University of Washington Medicine clinic in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, is reflected in a mirror, Thursday, Jan. 20, 2022, as he talks with a reporter after being given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Jose Lazaro, a medical assistant at a University of Washington Medicine clinic, prepares a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, right, who is immune-compromised, is given a shot of the two-shot dose of AstraZeneca's Evusheld — the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, by Jose Lazaro, center, a medical assistant at a University of Washington Medicine clinic in Seattle as Cynde Wiederhold, left, a nurse, looks on. The two-shot dose is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, holds a photo of himself taken in 2020 when he received a liver transplant, Thursday, Jan. 20, 2022, after he was given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Bottles and syringes holding a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, rest on a table, Thursday, Jan. 20, 2022 at a University of Washington Medicine clinic in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, is reflected in a mirror, Thursday, Jan. 20, 2022, as he talks with a reporter after being given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Jose Lazaro, a medical assistant at a University of Washington Medicine clinic, prepares a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, right, who is immune-compromised, is given a shot of the two-shot dose of AstraZeneca's Evusheld — the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, by Jose Lazaro, center, a medical assistant at a University of Washington Medicine clinic in Seattle as Cynde Wiederhold, left, a nurse, looks on. The two-shot dose is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, holds a photo of himself taken in 2020 when he received a liver transplant, Thursday, Jan. 20, 2022, after he was given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Bottles and syringes holding a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, rest on a table, Thursday, Jan. 20, 2022 at a University of Washington Medicine clinic in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, is reflected in a mirror, Thursday, Jan. 20, 2022, as he talks with a reporter after being given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Jose Lazaro, a medical assistant at a University of Washington Medicine clinic, prepares a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, right, who is immune-compromised, is given a shot of the two-shot dose of AstraZeneca's Evusheld — the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, by Jose Lazaro, center, a medical assistant at a University of Washington Medicine clinic in Seattle as Cynde Wiederhold, left, a nurse, looks on. The two-shot dose is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, holds a photo of himself taken in 2020 when he received a liver transplant, Thursday, Jan. 20, 2022, after he was given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Bottles and syringes holding a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, rest on a table, Thursday, Jan. 20, 2022 at a University of Washington Medicine clinic in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, is reflected in a mirror, Thursday, Jan. 20, 2022, as he talks with a reporter after being given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Jose Lazaro, a medical assistant at a University of Washington Medicine clinic, prepares a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, right, who is immune-compromised, is given a shot of the two-shot dose of AstraZeneca's Evusheld — the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, by Jose Lazaro, center, a medical assistant at a University of Washington Medicine clinic in Seattle as Cynde Wiederhold, left, a nurse, looks on. The two-shot dose is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, holds a photo of himself taken in 2020 when he received a liver transplant, Thursday, Jan. 20, 2022, after he was given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Bottles and syringes holding a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, rest on a table, Thursday, Jan. 20, 2022 at a University of Washington Medicine clinic in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, is reflected in a mirror, Thursday, Jan. 20, 2022, as he talks with a reporter after being given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Jose Lazaro, a medical assistant at a University of Washington Medicine clinic, prepares a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, right, who is immune-compromised, is given a shot of the two-shot dose of AstraZeneca's Evusheld — the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, by Jose Lazaro, center, a medical assistant at a University of Washington Medicine clinic in Seattle as Cynde Wiederhold, left, a nurse, looks on. The two-shot dose is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, holds a photo of himself taken in 2020 when he received a liver transplant, Thursday, Jan. 20, 2022, after he was given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Bottles and syringes holding a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, rest on a table, Thursday, Jan. 20, 2022 at a University of Washington Medicine clinic in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, is reflected in a mirror, Thursday, Jan. 20, 2022, as he talks with a reporter after being given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Jose Lazaro, a medical assistant at a University of Washington Medicine clinic, prepares a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, right, who is immune-compromised, is given a shot of the two-shot dose of AstraZeneca's Evusheld — the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, by Jose Lazaro, center, a medical assistant at a University of Washington Medicine clinic in Seattle as Cynde Wiederhold, left, a nurse, looks on. The two-shot dose is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, holds a photo of himself taken in 2020 when he received a liver transplant, Thursday, Jan. 20, 2022, after he was given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Bottles and syringes holding a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, rest on a table, Thursday, Jan. 20, 2022 at a University of Washington Medicine clinic in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, is reflected in a mirror, Thursday, Jan. 20, 2022, as he talks with a reporter after being given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Jose Lazaro, a medical assistant at a University of Washington Medicine clinic, prepares a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, right, who is immune-compromised, is given a shot of the two-shot dose of AstraZeneca's Evusheld — the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, by Jose Lazaro, center, a medical assistant at a University of Washington Medicine clinic in Seattle as Cynde Wiederhold, left, a nurse, looks on. The two-shot dose is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, holds a photo of himself taken in 2020 when he received a liver transplant, Thursday, Jan. 20, 2022, after he was given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Bottles and syringes holding a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, rest on a table, Thursday, Jan. 20, 2022 at a University of Washington Medicine clinic in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, is reflected in a mirror, Thursday, Jan. 20, 2022, as he talks with a reporter after being given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Jose Lazaro, a medical assistant at a University of Washington Medicine clinic, prepares a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, right, who is immune-compromised, is given a shot of the two-shot dose of AstraZeneca's Evusheld — the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, by Jose Lazaro, center, a medical assistant at a University of Washington Medicine clinic in Seattle as Cynde Wiederhold, left, a nurse, looks on. The two-shot dose is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, holds a photo of himself taken in 2020 when he received a liver transplant, Thursday, Jan. 20, 2022, after he was given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Bottles and syringes holding a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, rest on a table, Thursday, Jan. 20, 2022 at a University of Washington Medicine clinic in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, is reflected in a mirror, Thursday, Jan. 20, 2022, as he talks with a reporter after being given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Jose Lazaro, a medical assistant at a University of Washington Medicine clinic, prepares a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, right, who is immune-compromised, is given a shot of the two-shot dose of AstraZeneca's Evusheld — the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, by Jose Lazaro, center, a medical assistant at a University of Washington Medicine clinic in Seattle as Cynde Wiederhold, left, a nurse, looks on. The two-shot dose is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, holds a photo of himself taken in 2020 when he received a liver transplant, Thursday, Jan. 20, 2022, after he was given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Bottles and syringes holding a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, rest on a table, Thursday, Jan. 20, 2022 at a University of Washington Medicine clinic in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, is reflected in a mirror, Thursday, Jan. 20, 2022, as he talks with a reporter after being given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Jose Lazaro, a medical assistant at a University of Washington Medicine clinic, prepares a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, right, who is immune-compromised, is given a shot of the two-shot dose of AstraZeneca's Evusheld — the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, by Jose Lazaro, center, a medical assistant at a University of Washington Medicine clinic in Seattle as Cynde Wiederhold, left, a nurse, looks on. The two-shot dose is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, holds a photo of himself taken in 2020 when he received a liver transplant, Thursday, Jan. 20, 2022, after he was given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Bottles and syringes holding a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, rest on a table, Thursday, Jan. 20, 2022 at a University of Washington Medicine clinic in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, is reflected in a mirror, Thursday, Jan. 20, 2022, as he talks with a reporter after being given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Jose Lazaro, a medical assistant at a University of Washington Medicine clinic, prepares a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, right, who is immune-compromised, is given a shot of the two-shot dose of AstraZeneca's Evusheld — the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, by Jose Lazaro, center, a medical assistant at a University of Washington Medicine clinic in Seattle as Cynde Wiederhold, left, a nurse, looks on. The two-shot dose is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, holds a photo of himself taken in 2020 when he received a liver transplant, Thursday, Jan. 20, 2022, after he was given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Bottles and syringes holding a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, rest on a table, Thursday, Jan. 20, 2022 at a University of Washington Medicine clinic in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, is reflected in a mirror, Thursday, Jan. 20, 2022, as he talks with a reporter after being given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Jose Lazaro, a medical assistant at a University of Washington Medicine clinic, prepares a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, right, who is immune-compromised, is given a shot of the two-shot dose of AstraZeneca's Evusheld — the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, by Jose Lazaro, center, a medical assistant at a University of Washington Medicine clinic in Seattle as Cynde Wiederhold, left, a nurse, looks on. The two-shot dose is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, holds a photo of himself taken in 2020 when he received a liver transplant, Thursday, Jan. 20, 2022, after he was given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Bottles and syringes holding a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, rest on a table, Thursday, Jan. 20, 2022 at a University of Washington Medicine clinic in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, is reflected in a mirror, Thursday, Jan. 20, 2022, as he talks with a reporter after being given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Jose Lazaro, a medical assistant at a University of Washington Medicine clinic, prepares a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, right, who is immune-compromised, is given a shot of the two-shot dose of AstraZeneca's Evusheld — the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, by Jose Lazaro, center, a medical assistant at a University of Washington Medicine clinic in Seattle as Cynde Wiederhold, left, a nurse, looks on. The two-shot dose is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, holds a photo of himself taken in 2020 when he received a liver transplant, Thursday, Jan. 20, 2022, after he was given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Bottles and syringes holding a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, rest on a table, Thursday, Jan. 20, 2022 at a University of Washington Medicine clinic in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, is reflected in a mirror, Thursday, Jan. 20, 2022, as he talks with a reporter after being given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Jose Lazaro, a medical assistant at a University of Washington Medicine clinic, prepares a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, right, who is immune-compromised, is given a shot of the two-shot dose of AstraZeneca's Evusheld — the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, by Jose Lazaro, center, a medical assistant at a University of Washington Medicine clinic in Seattle as Cynde Wiederhold, left, a nurse, looks on. The two-shot dose is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, holds a photo of himself taken in 2020 when he received a liver transplant, Thursday, Jan. 20, 2022, after he was given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Bottles and syringes holding a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, rest on a table, Thursday, Jan. 20, 2022 at a University of Washington Medicine clinic in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, is reflected in a mirror, Thursday, Jan. 20, 2022, as he talks with a reporter after being given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Jose Lazaro, a medical assistant at a University of Washington Medicine clinic, prepares a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, right, who is immune-compromised, is given a shot of the two-shot dose of AstraZeneca's Evusheld — the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, by Jose Lazaro, center, a medical assistant at a University of Washington Medicine clinic in Seattle as Cynde Wiederhold, left, a nurse, looks on. The two-shot dose is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, holds a photo of himself taken in 2020 when he received a liver transplant, Thursday, Jan. 20, 2022, after he was given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Bottles and syringes holding a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, rest on a table, Thursday, Jan. 20, 2022 at a University of Washington Medicine clinic in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, is reflected in a mirror, Thursday, Jan. 20, 2022, as he talks with a reporter after being given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Jose Lazaro, a medical assistant at a University of Washington Medicine clinic, prepares a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, right, who is immune-compromised, is given a shot of the two-shot dose of AstraZeneca's Evusheld — the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, by Jose Lazaro, center, a medical assistant at a University of Washington Medicine clinic in Seattle as Cynde Wiederhold, left, a nurse, looks on. The two-shot dose is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, holds a photo of himself taken in 2020 when he received a liver transplant, Thursday, Jan. 20, 2022, after he was given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Bottles and syringes holding a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, rest on a table, Thursday, Jan. 20, 2022 at a University of Washington Medicine clinic in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, is reflected in a mirror, Thursday, Jan. 20, 2022, as he talks with a reporter after being given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Jose Lazaro, a medical assistant at a University of Washington Medicine clinic, prepares a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, right, who is immune-compromised, is given a shot of the two-shot dose of AstraZeneca's Evusheld — the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, by Jose Lazaro, center, a medical assistant at a University of Washington Medicine clinic in Seattle as Cynde Wiederhold, left, a nurse, looks on. The two-shot dose is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, holds a photo of himself taken in 2020 when he received a liver transplant, Thursday, Jan. 20, 2022, after he was given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Bottles and syringes holding a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, rest on a table, Thursday, Jan. 20, 2022 at a University of Washington Medicine clinic in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, is reflected in a mirror, Thursday, Jan. 20, 2022, as he talks with a reporter after being given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Jose Lazaro, a medical assistant at a University of Washington Medicine clinic, prepares a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, right, who is immune-compromised, is given a shot of the two-shot dose of AstraZeneca's Evusheld — the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, by Jose Lazaro, center, a medical assistant at a University of Washington Medicine clinic in Seattle as Cynde Wiederhold, left, a nurse, looks on. The two-shot dose is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, holds a photo of himself taken in 2020 when he received a liver transplant, Thursday, Jan. 20, 2022, after he was given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Bottles and syringes holding a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, rest on a table, Thursday, Jan. 20, 2022 at a University of Washington Medicine clinic in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, is reflected in a mirror, Thursday, Jan. 20, 2022, as he talks with a reporter after being given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Jose Lazaro, a medical assistant at a University of Washington Medicine clinic, prepares a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, right, who is immune-compromised, is given a shot of the two-shot dose of AstraZeneca's Evusheld — the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, by Jose Lazaro, center, a medical assistant at a University of Washington Medicine clinic in Seattle as Cynde Wiederhold, left, a nurse, looks on. The two-shot dose is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, holds a photo of himself taken in 2020 when he received a liver transplant, Thursday, Jan. 20, 2022, after he was given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Bottles and syringes holding a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, rest on a table, Thursday, Jan. 20, 2022 at a University of Washington Medicine clinic in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, is reflected in a mirror, Thursday, Jan. 20, 2022, as he talks with a reporter after being given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Jose Lazaro, a medical assistant at a University of Washington Medicine clinic, prepares a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, right, who is immune-compromised, is given a shot of the two-shot dose of AstraZeneca's Evusheld — the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, by Jose Lazaro, center, a medical assistant at a University of Washington Medicine clinic in Seattle as Cynde Wiederhold, left, a nurse, looks on. The two-shot dose is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, holds a photo of himself taken in 2020 when he received a liver transplant, Thursday, Jan. 20, 2022, after he was given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Bottles and syringes holding a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, rest on a table, Thursday, Jan. 20, 2022 at a University of Washington Medicine clinic in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, is reflected in a mirror, Thursday, Jan. 20, 2022, as he talks with a reporter after being given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Jose Lazaro, a medical assistant at a University of Washington Medicine clinic, prepares a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, right, who is immune-compromised, is given a shot of the two-shot dose of AstraZeneca's Evusheld — the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, by Jose Lazaro, center, a medical assistant at a University of Washington Medicine clinic in Seattle as Cynde Wiederhold, left, a nurse, looks on. The two-shot dose is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, holds a photo of himself taken in 2020 when he received a liver transplant, Thursday, Jan. 20, 2022, after he was given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Bottles and syringes holding a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, rest on a table, Thursday, Jan. 20, 2022 at a University of Washington Medicine clinic in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, is reflected in a mirror, Thursday, Jan. 20, 2022, as he talks with a reporter after being given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Jose Lazaro, a medical assistant at a University of Washington Medicine clinic, prepares a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, right, who is immune-compromised, is given a shot of the two-shot dose of AstraZeneca's Evusheld — the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, by Jose Lazaro, center, a medical assistant at a University of Washington Medicine clinic in Seattle as Cynde Wiederhold, left, a nurse, looks on. The two-shot dose is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, holds a photo of himself taken in 2020 when he received a liver transplant, Thursday, Jan. 20, 2022, after he was given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Bottles and syringes holding a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, rest on a table, Thursday, Jan. 20, 2022 at a University of Washington Medicine clinic in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, is reflected in a mirror, Thursday, Jan. 20, 2022, as he talks with a reporter after being given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Jose Lazaro, a medical assistant at a University of Washington Medicine clinic, prepares a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, right, who is immune-compromised, is given a shot of the two-shot dose of AstraZeneca's Evusheld — the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, by Jose Lazaro, center, a medical assistant at a University of Washington Medicine clinic in Seattle as Cynde Wiederhold, left, a nurse, looks on. The two-shot dose is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, holds a photo of himself taken in 2020 when he received a liver transplant, Thursday, Jan. 20, 2022, after he was given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Bottles and syringes holding a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, rest on a table, Thursday, Jan. 20, 2022 at a University of Washington Medicine clinic in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, is reflected in a mirror, Thursday, Jan. 20, 2022, as he talks with a reporter after being given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Jose Lazaro, a medical assistant at a University of Washington Medicine clinic, prepares a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, right, who is immune-compromised, is given a shot of the two-shot dose of AstraZeneca's Evusheld — the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, by Jose Lazaro, center, a medical assistant at a University of Washington Medicine clinic in Seattle as Cynde Wiederhold, left, a nurse, looks on. The two-shot dose is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, holds a photo of himself taken in 2020 when he received a liver transplant, Thursday, Jan. 20, 2022, after he was given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Bottles and syringes holding a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, rest on a table, Thursday, Jan. 20, 2022 at a University of Washington Medicine clinic in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, is reflected in a mirror, Thursday, Jan. 20, 2022, as he talks with a reporter after being given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Jose Lazaro, a medical assistant at a University of Washington Medicine clinic, prepares a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, right, who is immune-compromised, is given a shot of the two-shot dose of AstraZeneca's Evusheld — the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, by Jose Lazaro, center, a medical assistant at a University of Washington Medicine clinic in Seattle as Cynde Wiederhold, left, a nurse, looks on. The two-shot dose is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, holds a photo of himself taken in 2020 when he received a liver transplant, Thursday, Jan. 20, 2022, after he was given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Bottles and syringes holding a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, rest on a table, Thursday, Jan. 20, 2022 at a University of Washington Medicine clinic in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, is reflected in a mirror, Thursday, Jan. 20, 2022, as he talks with a reporter after being given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Jose Lazaro, a medical assistant at a University of Washington Medicine clinic, prepares a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, right, who is immune-compromised, is given a shot of the two-shot dose of AstraZeneca's Evusheld — the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, by Jose Lazaro, center, a medical assistant at a University of Washington Medicine clinic in Seattle as Cynde Wiederhold, left, a nurse, looks on. The two-shot dose is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, holds a photo of himself taken in 2020 when he received a liver transplant, Thursday, Jan. 20, 2022, after he was given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Bottles and syringes holding a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, rest on a table, Thursday, Jan. 20, 2022 at a University of Washington Medicine clinic in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, is reflected in a mirror, Thursday, Jan. 20, 2022, as he talks with a reporter after being given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Jose Lazaro, a medical assistant at a University of Washington Medicine clinic, prepares a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, right, who is immune-compromised, is given a shot of the two-shot dose of AstraZeneca's Evusheld — the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, by Jose Lazaro, center, a medical assistant at a University of Washington Medicine clinic in Seattle as Cynde Wiederhold, left, a nurse, looks on. The two-shot dose is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, holds a photo of himself taken in 2020 when he received a liver transplant, Thursday, Jan. 20, 2022, after he was given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Bottles and syringes holding a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, rest on a table, Thursday, Jan. 20, 2022 at a University of Washington Medicine clinic in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, is reflected in a mirror, Thursday, Jan. 20, 2022, as he talks with a reporter after being given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Jose Lazaro, a medical assistant at a University of Washington Medicine clinic, prepares a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, right, who is immune-compromised, is given a shot of the two-shot dose of AstraZeneca's Evusheld — the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, by Jose Lazaro, center, a medical assistant at a University of Washington Medicine clinic in Seattle as Cynde Wiederhold, left, a nurse, looks on. The two-shot dose is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, holds a photo of himself taken in 2020 when he received a liver transplant, Thursday, Jan. 20, 2022, after he was given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Bottles and syringes holding a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, rest on a table, Thursday, Jan. 20, 2022 at a University of Washington Medicine clinic in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, is reflected in a mirror, Thursday, Jan. 20, 2022, as he talks with a reporter after being given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Jose Lazaro, a medical assistant at a University of Washington Medicine clinic, prepares a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, right, who is immune-compromised, is given a shot of the two-shot dose of AstraZeneca's Evusheld — the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, by Jose Lazaro, center, a medical assistant at a University of Washington Medicine clinic in Seattle as Cynde Wiederhold, left, a nurse, looks on. The two-shot dose is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, holds a photo of himself taken in 2020 when he received a liver transplant, Thursday, Jan. 20, 2022, after he was given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Bottles and syringes holding a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, rest on a table, Thursday, Jan. 20, 2022 at a University of Washington Medicine clinic in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, is reflected in a mirror, Thursday, Jan. 20, 2022, as he talks with a reporter after being given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Jose Lazaro, a medical assistant at a University of Washington Medicine clinic, prepares a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, right, who is immune-compromised, is given a shot of the two-shot dose of AstraZeneca's Evusheld — the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, by Jose Lazaro, center, a medical assistant at a University of Washington Medicine clinic in Seattle as Cynde Wiederhold, left, a nurse, looks on. The two-shot dose is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, holds a photo of himself taken in 2020 when he received a liver transplant, Thursday, Jan. 20, 2022, after he was given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Bottles and syringes holding a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, rest on a table, Thursday, Jan. 20, 2022 at a University of Washington Medicine clinic in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, is reflected in a mirror, Thursday, Jan. 20, 2022, as he talks with a reporter after being given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Jose Lazaro, a medical assistant at a University of Washington Medicine clinic, prepares a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, right, who is immune-compromised, is given a shot of the two-shot dose of AstraZeneca's Evusheld — the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, by Jose Lazaro, center, a medical assistant at a University of Washington Medicine clinic in Seattle as Cynde Wiederhold, left, a nurse, looks on. The two-shot dose is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, holds a photo of himself taken in 2020 when he received a liver transplant, Thursday, Jan. 20, 2022, after he was given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Bottles and syringes holding a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, rest on a table, Thursday, Jan. 20, 2022 at a University of Washington Medicine clinic in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, is reflected in a mirror, Thursday, Jan. 20, 2022, as he talks with a reporter after being given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Jose Lazaro, a medical assistant at a University of Washington Medicine clinic, prepares a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, right, who is immune-compromised, is given a shot of the two-shot dose of AstraZeneca's Evusheld — the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, by Jose Lazaro, center, a medical assistant at a University of Washington Medicine clinic in Seattle as Cynde Wiederhold, left, a nurse, looks on. The two-shot dose is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, holds a photo of himself taken in 2020 when he received a liver transplant, Thursday, Jan. 20, 2022, after he was given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Bottles and syringes holding a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, rest on a table, Thursday, Jan. 20, 2022 at a University of Washington Medicine clinic in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, is reflected in a mirror, Thursday, Jan. 20, 2022, as he talks with a reporter after being given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Jose Lazaro, a medical assistant at a University of Washington Medicine clinic, prepares a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, right, who is immune-compromised, is given a shot of the two-shot dose of AstraZeneca's Evusheld — the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, by Jose Lazaro, center, a medical assistant at a University of Washington Medicine clinic in Seattle as Cynde Wiederhold, left, a nurse, looks on. The two-shot dose is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, holds a photo of himself taken in 2020 when he received a liver transplant, Thursday, Jan. 20, 2022, after he was given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Bottles and syringes holding a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, rest on a table, Thursday, Jan. 20, 2022 at a University of Washington Medicine clinic in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, is reflected in a mirror, Thursday, Jan. 20, 2022, as he talks with a reporter after being given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Jose Lazaro, a medical assistant at a University of Washington Medicine clinic, prepares a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, right, who is immune-compromised, is given a shot of the two-shot dose of AstraZeneca's Evusheld — the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, by Jose Lazaro, center, a medical assistant at a University of Washington Medicine clinic in Seattle as Cynde Wiederhold, left, a nurse, looks on. The two-shot dose is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, holds a photo of himself taken in 2020 when he received a liver transplant, Thursday, Jan. 20, 2022, after he was given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Bottles and syringes holding a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, rest on a table, Thursday, Jan. 20, 2022 at a University of Washington Medicine clinic in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, is reflected in a mirror, Thursday, Jan. 20, 2022, as he talks with a reporter after being given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Jose Lazaro, a medical assistant at a University of Washington Medicine clinic, prepares a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, right, who is immune-compromised, is given a shot of the two-shot dose of AstraZeneca's Evusheld — the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, by Jose Lazaro, center, a medical assistant at a University of Washington Medicine clinic in Seattle as Cynde Wiederhold, left, a nurse, looks on. The two-shot dose is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, holds a photo of himself taken in 2020 when he received a liver transplant, Thursday, Jan. 20, 2022, after he was given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Bottles and syringes holding a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, rest on a table, Thursday, Jan. 20, 2022 at a University of Washington Medicine clinic in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, is reflected in a mirror, Thursday, Jan. 20, 2022, as he talks with a reporter after being given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Jose Lazaro, a medical assistant at a University of Washington Medicine clinic, prepares a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, right, who is immune-compromised, is given a shot of the two-shot dose of AstraZeneca's Evusheld — the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, by Jose Lazaro, center, a medical assistant at a University of Washington Medicine clinic in Seattle as Cynde Wiederhold, left, a nurse, looks on. The two-shot dose is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, holds a photo of himself taken in 2020 when he received a liver transplant, Thursday, Jan. 20, 2022, after he was given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Bottles and syringes holding a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, rest on a table, Thursday, Jan. 20, 2022 at a University of Washington Medicine clinic in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, is reflected in a mirror, Thursday, Jan. 20, 2022, as he talks with a reporter after being given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Jose Lazaro, a medical assistant at a University of Washington Medicine clinic, prepares a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, in Seattle. The drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, right, who is immune-compromised, is given a shot of the two-shot dose of AstraZeneca's Evusheld — the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, by Jose Lazaro, center, a medical assistant at a University of Washington Medicine clinic in Seattle as Cynde Wiederhold, left, a nurse, looks on. The two-shot dose is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, who is immune-compromised, holds a photo of himself taken in 2020 when he received a liver transplant, Thursday, Jan. 20, 2022, after he was given a two-shot dose of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, at a University of Washington Medicine clinic in Seattle. The drug is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Scott Madow, a heath services manager at a University of Washington Medicine clinic, poses for a photo as he holds a box of AstraZeneca's Evusheld, the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, in Seattle. A two-shot dose of the drug is supposed to give immune-compromised patients who can't make their own virus-fighters some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) This family photo shows Jackie Hansen at the University of Pittsburgh Medical Center on Wednesday, Jan. 26, 2022. Hansen’s immune system is so wrecked by cancer and lupus that COVID-19 vaccinations couldn’t take hold, leaving her essentially a prisoner in her home two years into the pandemic and counting. Then she finally got access to scarce doses of the first drug that promises six months of protection for people with no other way to fend off the virus. (Rolf Hansen via AP) Ray Hoffman, who is immune-compromised, is given a shot of the two-shot dose of AstraZeneca's Evusheld — the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, by Jose Lazaro, a medical assistant at a University of Washington Medicine clinic in Seattle. The two-shot dose is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren) Ray Hoffman, right, who is immune-compromised, is given a shot of the two-shot dose of AstraZeneca's Evusheld — the first set of antibodies grown in a lab to prevent COVID-19, Thursday, Jan. 20, 2022, by Jose Lazaro, center, a medical assistant at a University of Washington Medicine clinic in Seattle as Cynde Wiederhold, left, a nurse, looks on. The two-shot dose is supposed to give patients like Hoffman, who can't make his own virus-fighters due to taking strong immune-suppressing drugs after liver and kidney transplants, some protection against COVID-19 for six months. (AP Photo/Ted S. Warren)